Karyopharm Therapeutics Inc. KPTIQ

Company Overview

Karyopharm Therapeutics Inc. is a U.S.-based commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel cancer therapies. The company operates primarily in the oncology sector and is best known for developing selective inhibitors of nuclear export (SINE) compounds that target exportin 1 (XPO1), a protein involved in transporting tumor suppressor proteins out of the cell nucleus. Karyopharm’s lead commercial product is XPOVIO (selinexor), which has received regulatory approvals in multiple hematologic cancer indications, including multiple myeloma and diffuse large B-cell lymphoma. The company also has pipeline programs evaluating selinexor and related compounds in both hematologic malignancies and solid tumors.

Karyopharm was founded in 2008 and is headquartered in Newton, Massachusetts. The company evolved from a research-focused biotechnology enterprise into a commercial oncology company following the U.S. Food and Drug Administration approval of XPOVIO in 2019. Its strategic positioning centers on proprietary expertise in nuclear export biology and the development of orally administered therapies for difficult-to-treat cancers. Revenue has historically been driven primarily by product sales of XPOVIO and collaboration-related activities tied to international licensing and commercialization agreements.

Business Operations

Karyopharm’s operations are centered on oncology drug development and commercialization through its core therapeutic platform targeting nuclear export pathways. The company’s primary operating activities include clinical research and development, regulatory affairs, manufacturing oversight, and commercialization of XPOVIO. Revenue is generated mainly through U.S. product sales, milestone and licensing payments, and collaboration arrangements with international partners. The company has historically reported a single operating segment focused on pharmaceutical development and commercialization.

The company maintains commercial operations primarily in the United States while leveraging international partners for broader geographic reach. Karyopharm has entered into licensing and commercialization partnerships involving XPOVIO in markets outside the U.S., including agreements with regional pharmaceutical companies in Asia and other international territories. Its proprietary SINE technology platform and intellectual property portfolio represent key strategic assets. The company also maintains relationships with contract research organizations, manufacturers, and clinical trial partners to support development and supply chain operations.

Strategic Position & Investments

Karyopharm’s strategic direction has focused on expanding the clinical utility of selinexor through additional indications, combination therapies, and earlier-line treatment settings. The company has invested significantly in clinical trials evaluating selinexor in multiple myeloma, myelodysplastic syndromes, endometrial cancer, and myelofibrosis, among other oncology indications. Its strategy emphasizes maximizing the value of existing oncology assets while managing operating expenses and prioritizing late-stage development opportunities with clearer commercial potential.

In addition to selinexor, Karyopharm has advanced other SINE compounds through preclinical and clinical development, including eltanexor, a second-generation XPO1 inhibitor. The company has also pursued international commercialization partnerships as a capital-efficient approach to geographic expansion. Strategic collaborations and licensing arrangements have played an important role in extending market access while reducing the need for direct commercial infrastructure outside the United States. Public disclosures indicate ongoing efforts to evaluate business development opportunities and optimize its oncology pipeline portfolio.

Geographic Footprint

Karyopharm is headquartered in Newton, Massachusetts, and its primary commercial market is the United States. The company’s approved oncology products are marketed domestically through its internal commercial organization, particularly targeting hematologists and oncologists treating blood cancers. Clinical development activities involve trial sites across North America, Europe, and parts of Asia through collaborations with hospitals, cancer centers, and research institutions.

Internationally, Karyopharm has expanded its presence through licensing and commercialization agreements covering regions including Europe, Asia-Pacific, and select emerging markets. The company’s products and development programs have had regulatory and clinical engagement in countries such as China and other international oncology markets through regional partners. While its direct operational footprint remains concentrated in the United States, its therapeutic programs and licensing relationships provide broader global exposure within the oncology sector.

Leadership & Governance

Karyopharm is governed by a board of directors and executive leadership team with backgrounds in biotechnology, oncology drug development, commercialization, and finance. The company’s leadership strategy has emphasized advancing differentiated oncology therapies through focused clinical development, disciplined capital allocation, and targeted commercialization in hematologic malignancies. Since its founding, Karyopharm has transitioned from an early-stage research organization into a publicly traded commercial oncology company listed on Nasdaq under the ticker KPTI.

Key executives and leaders include:

• Richard Paulson – President and Chief Executive Officer
• Sharon Shacham, Ph.D. – Founder, Chief Scientific Officer, and Board Director
• Michael G. Kauffman, M.D., Ph.D. – Former Chief Executive Officer and Board leadership figure
• Matthew J. Kulp – Executive Vice President and Chief Financial Officer
• Reshma Rangwala, M.D., Ph.D. – Chief Medical Officer
• Christopher Brett – Senior commercial leadership executive associated with oncology commercialization activities

The company’s governance framework follows standard public biotechnology company practices, including oversight through independent directors, audit and compensation committees, and disclosures filed through SEC filings including annual reports on Form 10-K and quarterly reports on Form 10-Q.